Pure Global AI
NCT05874804Not yet recruiting

Carry Life@ UF System Clinical Study

A Clinical Study With the Carry Life® UF System in Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients
Triomed ABClinicalTrials.govdeviceDevice trial
Verified
Study focus
Disease/Condition
End Stage Renal Disease
Drug/Device/Intervention
Carry Life UF
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Triomed AB
Timeline & enrollment
Phase
N/A
Start date
Aug 01, 2023
End date
Aug 01, 2024
Enrollment
25 participants
Primary outcome

Ultrafiltration volume

Summary

The Carry Life UF system performs peritoneal ultrafiltration by adding glucose to the low
 glucose strength (1.36%) peritoneal dialysis fluid which has been instilled into the
 peritoneal cavity prior to the connection of the device. By maintaining a stable glucose
 concentration in the intraperitoneal fluid during the 5-hour treatment, the ultrafiltration
 can be increased compared to a standard CAPD dwell.

ICD-10 classifications
Chronic kidney disease, stage 1Chronic kidney disease, stage 5Chronic kidney disease, stage 2Chronic kidney disease, stage 3Chronic kidney disease, stage 4
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05874804
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT05874804 through Pure Global AI's free database. This phase not specified trial is sponsored by Triomed AB and is currently Not yet recruiting. The study focuses on End Stage Renal Disease. Target enrollment is 25 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.